A study on correlation of histopathological grade with hormone receptor and HER2/neu status in invasive breast carcinoma at a tertiary care centre of Barak valley
Keywords:Breast carcinoma, Invasive ductal carcinoma, Estrogen receptor, Progesteron receptor, HER2/neu
Background: Breast carcinoma is the most common malignancy occurring in females worldwide while in India it is the 2nd most common malignancy occurring after cervical cancer in females. The treatment modalities and prognosis of breast carcinoma depend largely on their hormone receptors (estrogen and progesterone receptors) and human epidermal growth factor receptor 2 (HER2/neu) status. The aim of this study was to correlate the receptor status in invasive breast carcinoma with histopathological grading of the tumor.
Methods: This is a retrospective study carried out in the department of pathology, Silchar medical college and hospital, Cachar from January 2019 to December 2020. A total of 69 cases were considered for the study, selected on the basis of inclusion and exclusion criteria. Histomorphology grading in invasive ductal breast carcinomas was done along with the status of estrogen receptor (ER), progesterone receptor (PR) and HER2/neu.
Results: The present study comprised of total of 69 infiltrating breast carcinoma cases. Out of all 51% cases were found to be in 4th decade of life. The most common type found in the study was invasive ductal carcinoma (not otherwise specified) seen in 86.96% cases. Maximum 41.67% of cases were histologically classified as grade III. A positive correlation was found between histological grading and immunohistochemistry of hormone receptors (ER, PR) and HER2/neu status.
Conclusions: From the present study, it can be concluded that there is a positive correlation between histopathological grade and hormone receptors status and HER2/neu.The estrogen receptor and progestrone receptor were found negative in high grade disease on histological evaluation. Triple negative breast carcinomas have poorer prognosis as they tend to be of high grade.
Harirchi I, Kolahdoozan S, Karbakhsh M, CheginiS, MohseniSM, Montazeri A, et al. Twenty years of breast cancer in Iran: downstaging without a formal screening program. Ann Oncol. 2011;22(1):93-7.
Kumar N, Mukherjee S. Correlation of various prognostic factors in breast cancer. Int J Scient Res. 2013;3:1-4.
Amit M, Prasad C, Sreeramulu P, Srinivasan D, Naveedahmed K, Ruta UJ. Histopathological grade versus estrogen and progestron receptor status in carcinoma breast-a single center study. Open Acc J Surg. 2017;4(3):555639.
Roy I, Othieno E. Breast carcinoma in Uganda: microscopic study and receptor profile of 45 cases. Arch Pathol Lab Med. 2011;135(2):194-9.
Azizun-Nisa, Bhurgri Y, Reza F, Kayani N. Comparision of ER, PR and HER-2/neu (C-erb B2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer. Asian Pac J Cancer Prev. 2008;9(4):553-6.
Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11(2):155-68.
Gupta D, Gupta V, Marwah N, Gill M, Gupta S, Gupta G. Correlation of hormone receptor expression with histologic parameters in benign and malignant breast tumor. Iran J Pathol. 2015;10:23-34.
Chen XS, Ma CD, Wu JY, Yang WT, Lu HF, WuJ, et al. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer. Tumori. 2010;96(1):103-10
Onoda T, Yamauchi H, Yagata H, Tsugawa K, Hayashi N, Yoshida A, et al. The value of progesterone receptor expression in predicting the recurrence score for hormone-receptor positive invasive breast cancer patients. Breast Cancer. 2015;22(4):406-12.
Ambroise M, Ghosh M, Mallikarjuna VS, Kurian A. Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India. Asian Pac J Cancer Prev. 2011;12(3):625-9.
Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957;11(3):359-77.
Rosai J. Rosai and Ackerman’s Surgical Pathology. 9th ed. Noida: Reed Elsevier India Private Limited; 2009: 1787-827.
Umemura S, Kurosumi M, Moriya T, Oyama T, Arihiro K, Yamashita H, et al. Immunohistochemical evaluation for hormone receptors in breast cancer: a pratically useful evaluation system and handling protocol. Breast Cancer. 2006;13(3):232-5.
Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch.Pathol Lab Med. 2007;131(1):18-43.
Sondik EJ. Breast cancer trends. Incidence, mortality and survival. Cancer. 1994;74:995-9.
Moore DH, Moore DH, Moore CT. Breast carcinoma etiological factors. Adv Cancer Res. 1983;40:189-253
Mudduwa LK. Quick score of hormone receptor status of breast carcinoma: correlation with the other clinicopathological prognostic parameters. Indian J Pathol Microbiol. 2009;52(2):159-63.
Kaul R, Sharma J, Minhas SS, Mardi K. Hormone receptor status of breast cancer in the himalayan region of northern India. Indian J Surg. 2011;73(1):9-12.
Ejam SS, Farhood RG. Estrogen and progesterone receptors overexpression in breast carcinoma and their correlation with ages of patients, histopathological types and grades of tumors. Med J Babylon. 2013;10(3):726-34.
Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and HER2/neu expression: Comparison of clinicopathologic features and survival. Clin Med Res. 2009;7(1-2):4-13.
Ghosh J, Gupta S, Desai S, Shet T, Radhakrishnan S, Suryavanshi P, et al. Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India. Indian J Cancer. 2011;48(4):391-6.
Dixon JM, Page DL, Anderson TJ, Lee D, Elton RA, Stewart HJ, et al. Long-term survivors after breast cancer. Br J Surg. 1985;72(6):445-8.
Humphrey PA, Dehner LP, Pfeifer JD. Washington Manual of Surgical Pathology. 1st ed. Philadelphia: Lippincott Williams and Wilkins; 2008: 256-8.
Nikhra P, Patel S, Taviad D, Chaudhary S. Study of ER (estrogen receptor), PR (Progesterone Receptor) and HER-2/NEU (Human epidermal growth factor receptor) expression by immunohistochemistry in breast carcinoma. IJBAR. 2014;5:275-8.
Sofi GN, Nabi J, Nadeem R, Khan FA, Sofi AA, Bhat HA, et al. Estrogen receptor and progesterone receptor status in breast cancer in relation to age, histological grade, size of lesion and lymph node involvement. Asian Pacific J Cancer Prev. 2012;13(10):5047-52.
Bancroft JD, Gamble M. Theory and Practice of Histological Techniques. 5th ed. London: Churchill Livingstone; 2002: 493-517.
Fuqua SA, Schiff R, Parra I, Moore JT, Mohsin SK, Osborne CK, et al. Estrogen receptor beta protein in human breast cancer: Correlation with clinical tumor parameters. Cancer Res. 2003;63(10):2434-9.
Mohsin SK. Molecular markers in invasive breast cancer. Foundation in Diagnostic Pathology. 1st ed. Edinburgh: Churchill Livingstone; 2006: 266-9.
De Potter CR, Schelfhout AM. The neu-protein and breast cancer. Virchows Arch. 1995;426(1):107-15
Rosen PP, Menendez-Botet CJ, Nisselbaum JS, Urban JA, Miké V, Fracchia A, et al. Pathological review of breast lesions analyzed for estrogen receptor protein. Cancer Res. 1975;35:3187-94.
Jovicic-Milentijevic M, Ilic R, Katic V, Zivkovic V. Correlation of steroid hormone receptor status with histological and nuclear grading in breast carcinoma. J BUON. 2004;9:173-7.